These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 24638957)

  • 41. Humoral immunity in myasthenia gravis: immunoglobulin class, affinity, and antigenic site.
    Tindall RS
    Trans Am Neurol Assoc; 1979; 104():16-8. PubMed ID: 553397
    [No Abstract]   [Full Text] [Related]  

  • 42. Myasthenia gravis and related disorders: Pathology and molecular pathogenesis.
    Ha JC; Richman DP
    Biochim Biophys Acta; 2015 Apr; 1852(4):651-7. PubMed ID: 25486268
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Double seronegative myasthenia gravis with low density lipoprotein-4 (LRP4) antibodies presenting with isolated ocular symptoms.
    Tsivgoulis G; Dervenoulas G; Kokotis P; Zompola C; Tzartos JS; Tzartos SJ; Voumvourakis KI
    J Neurol Sci; 2014 Nov; 346(1-2):328-30. PubMed ID: 25248951
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Autoantibodies to Low-Density Lipoprotein Receptor-Related Protein 4 in Double Seronegative Myasthenia Gravis: A Systematic Review.
    Bacchi S; Kramer P; Chalk C
    Can J Neurol Sci; 2018 Jan; 45(1):62-67. PubMed ID: 29334041
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Thymoma-associated myasthenia gravis without acetylcholine receptor antibodies.
    Rigamonti A; Lauria G; Piamarta F; Fiumani A; Agostoni E
    J Neurol Sci; 2011 Mar; 302(1-2):112-3. PubMed ID: 21236448
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The pathogenesis of myasthenia gravis.
    Fulpius BW
    Bull Schweiz Akad Med Wiss; 1978 Mar; 34(1-3):25-31. PubMed ID: 667413
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Plasmapheresis and immunosuppressive drug therapy in myasthenia gravis.
    Dau PC; Lindstrom JM; Cassel CK; Denys EH; Shev EE; Spitler LE
    N Engl J Med; 1977 Nov; 297(21):1134-40. PubMed ID: 917042
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Increased uptake of acetylcholine-receptor antibody at motor endplate in myasthenic exacerbation.
    de Crousaz G; Fulpius BW
    Lancet; 1978 Jan; 1(8054):47. PubMed ID: 74528
    [No Abstract]   [Full Text] [Related]  

  • 49. [Pathogenesis and pathophysiology of myasthenia gravis--electrophysiological, ultrastructural and immunological aspects of neuromuscular junctions (author's transl)].
    Takamori M; Tsujihata M; Ide Y; Eguchi K; Mine M
    No To Shinkei; 1980 Sep; 32(9):891-908. PubMed ID: 6254548
    [No Abstract]   [Full Text] [Related]  

  • 50. Serological follow-up in juvenile myasthenia: clinical and acetylcholine receptor antibody status of patients followed for at least 2 years.
    Anlar B; Senbil N; Köse G; Değerliyurt A
    Neuromuscul Disord; 2005 May; 15(5):355-7. PubMed ID: 15833428
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Accessibility to antibodies of acetylcholine receptors in the neuromuscular junction.
    Zurn AD; Fulpius BW
    Clin Exp Immunol; 1976 Apr; 24(1):9-17. PubMed ID: 949876
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Acetylcholine receptor turnover in mice with passively transferred myasthenia gravis. II. Receptor synthesis.
    Wilson S; Vincent A; Newsom-Davis J
    J Neurol Neurosurg Psychiatry; 1983 May; 46(5):383-7. PubMed ID: 6101172
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Pseudo-internuclear ophthalmoplegia in myasthenia gravis].
    Bogdan I; Crisanda V
    Oftalmologia; 2011; 55(3):70-3. PubMed ID: 22428294
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pre- and postsynaptic neuromuscular junction abnormalities in musk myasthenia.
    Niks EH; Kuks JB; Wokke JH; Veldman H; Bakker E; Verschuuren JJ; Plomp JJ
    Muscle Nerve; 2010 Aug; 42(2):283-8. PubMed ID: 20544919
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Vocal cord paralysis in myasthenia gravis with anti-MuSK antibodies.
    Hara K; Mashima T; Matsuda A; Tanaka K; Tomita M; Shiraishi H; Motomura M; Nishizawa M
    Neurology; 2007 Feb; 68(8):621-2. PubMed ID: 17310039
    [No Abstract]   [Full Text] [Related]  

  • 56. Double Seropositive Myasthenia Gravis: A 5-Year Follow-Up.
    Zouvelou V
    Muscle Nerve; 2018 May; 57(5):E129. PubMed ID: 29240239
    [No Abstract]   [Full Text] [Related]  

  • 57. Antibodies to low density lipoprotein receptor-related protein 4 in seronegative myasthenia gravis.
    Richman DP
    Arch Neurol; 2012 Apr; 69(4):434-5. PubMed ID: 22158717
    [No Abstract]   [Full Text] [Related]  

  • 58. Cellular immune response to acetylcholine receptor-rich fraction, in patients with myasthenia gravis.
    Abramsky O; Aharonov A; Webb C; Fuchs S
    Clin Exp Immunol; 1975 Jan; 19(1):11-6. PubMed ID: 1239345
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Experimental myasthenia: lack of correlation between the autoantibody titer and the reduction of acetylcholine-controlled ionic channels measured at functioning endplates.
    Hohlfeld R; Sterz R; Kalies I; Wekerle H; Peper K
    Muscle Nerve; 1983 Feb; 6(2):160-3. PubMed ID: 6304508
    [No Abstract]   [Full Text] [Related]  

  • 60. Myasthenia gravis: State of the art and new therapeutic strategies.
    Souto EB; Lima B; Campos JR; Martins-Gomes C; Souto SB; Silva AM
    J Neuroimmunol; 2019 Dec; 337():577080. PubMed ID: 31670062
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.